In the latest trading session, 1.03 million Baudax Bio Inc. (NASDAQ:BXRX) shares changed hands as the company’s beta touched 0. With the company’s most recent per share price at $0.79 changing hands around $0.01 or 1.50% at last look, the market valuation stands at $66.13M. BXRX’s current price is a discount, trading about -498.73% off its 52-week high of $4.73. The share price had its 52-week low at $0.75, which suggests the last value was 5.06% up since then. When we look at Baudax Bio Inc.’s average trading volume, we note the 10-day average is 1.7 million shares, with the 3-month average coming to 1.89 million.
Analysts gave the Baudax Bio Inc. (BXRX) stock a consensus recommendation rating of a Buy, calculated at a mean rating of 1.70. If we narrow down to specifics, the data shows that 0 out of 3 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 0 recommended BXRX as a Hold, 3 felt it is a Buy and 0 rated the stock as Underweight. Baudax Bio Inc.’s EPS for the current quarter is expected to be -$0.2.
Baudax Bio Inc. (NASDAQ:BXRX) trade information
Instantly BXRX is in green as seen in intraday trades today. With action -7.63%, the performance over the past five days has been red. The jump to weekly highs of 0.8349 on Friday, 06/18/21 added 1.50% to the stock’s daily price. The company’s shares are showing year-to-date downside of -22.73%, with the 5-day performance at -7.63% in the red. However, in the 30-day time frame, Baudax Bio Inc. (NASDAQ:BXRX) is -9.78% down. Looking at the short shares, we see there were 4.76 million shares sold at short interest cover period of 2.55 days.
The consensus price target for the stock as assigned by Wall Street analysts is $3.67, meaning bulls need an upside of 78.47% from its recent market value. According to analyst projections, BXRX’s forecast low is $2.00 with $5.00 as the target high. To hit the forecast high, the stock’s price needs a -532.91% plunge from its current level, while the stock would need to soar -153.16% for it to hit the projected low.
Baudax Bio Inc. (BXRX) estimates and forecasts
Data shows that the Baudax Bio Inc. share is performing relatively much better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot -24.96% over the past 6 months, a 78.88% in annual growth rate that is considerably higher than the industry average of 16.40%. Moreover, analysts have looked to higher expectations by upgrading its fiscal year 2021 revenue estimates. The rating firms predict current quarter revenue for Baudax Bio Inc. will rise 88.40%, while the growth in revenue is estimated to hit -132.30% for the next quarter. Year-over-year growth is forecast to reach 609.90% up from the last financial year.
Consensus estimates given by 3 financial analysts project the company’s revenue in the current quarter to hit an average of $470k. 3 analysts are of the opinion that Baudax Bio Inc.’s revenue for the quarter ending Sep 2021 will be $1 million. The company’s revenue for the corresponding quarters a year ago was $349k and $68k respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 34.70%. The estimates for the next quarter sales put growth at 1,370.60%.
The 2021 estimates are for Baudax Bio Inc. earnings to decrease by -12.90%.
Baudax Bio Inc. (NASDAQ:BXRX)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 0.94% of Baudax Bio Inc. shares while 13.75% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 13.89%. There are 13.75% institutions holding the Baudax Bio Inc. stock share, with Vanguard Group, Inc. (The) the top institutional holder. As of Mar 30, 2021, the company held 5.54% of the shares, roughly 3.89 million BXRX shares worth $5.02 million.
Blackrock Inc. holds the second largest percentage of outstanding shares, with 2.06% or 1.45 million shares worth $1.86 million as of Mar 30, 2021.
Among Mutual Funds, the top two as of Mar 30, 2021 were Fidelity Extended Market Index Fund and Vanguard Total Stock Market Index Fund. With 0.31 million shares estimated at $0.4 million under it, the former controlled 0.44% of total outstanding shares. On the other hand, Vanguard Total Stock Market Index Fund held about 0.38% of the shares, roughly 0.27 million shares worth around $0.27 million.